Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Abstract

Sufficient ocular bioavailability is often considered a challenge by the researchers, due to the complex structure of the eye and its protective physiological mechanisms. In addition, the low viscosity of the eye drops and the resulting short ocular residence time further contribute to the observed low drug concentration at the target site. Therefore, various drug delivery platforms are being developed to enhance ocular bioavailability, provide controlled and sustained drug release, reduce the number of applications, and maximize therapy outcomes. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) exhibit all these benefits, in addition to being biocompatible, biodegradable, and susceptible to sterilization and scale-up. Furthermore, their successive surface modification contributes to prolonged ocular residence time (by adding cationic compounds), enhanced penetration, and improved performance. The review highlights the salient characteristics of SLNs and NLCs concerning ocular drug delivery, and updates the research progress in this area.

Oküler İlaç Taşiyici Si̇stem Olarak Li̇pi̇t Bazli Nanoparti̇küller

“…Bahsedilen tüm lipit bazlı nanotaşıyıcıların oftalmolojideki kullanılabilirliklerini özetleyen bir inceleme burada sunulmaktadır [13]. Başlangıçta üstün fiziksel stabiliteleri, düşük maliyetli üretim malzemelerine ve süreçlerine sahip olmalarıyla lipozomlara alternatif olarak ortaya çıkan ve aynı zamanda toksik bozunma ürünleri bulunmamasından dolayı polimerik nanopartiküller yerine değerlendirilen KLN'ler, çeşitli uygulama yollarına yönelik geliştirilerek dermal, oküler, pulmoner, parenteral ve oral ilaç taşıyıcı sistemler olarak araştırılmıştır [14]. Lipit nanotaşıyıcıların bir başka özelliği de birden fazla terapötik ajanı enkapsüle edebilmesidir.…”

Current Innovations in Intraocular Pressure Monitoring Biosensors for Diagnosis and Treatment of Glaucoma—Novel Strategies and Future Perspectives

“…The lacrimal duct secretes the middle aqueous layer of the tear film, which serves as a lubricant and shields the ocular surface [ 33 ]. The tear film, which is frequently referred to as a dynamic (physiological) ocular barrier due to its rapid turnover rate, brief ocular residence time and restricted drug penetration ability, is the first barrier for topically applied drugs [ 34 ]. Various factors such as the composition, stability and integrity of the tear film play a vital role in the development of dry eye disease (DED) [ 35 ].…”

New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment

“…1B), having a close relationship with liposomes described above but featuring much higher drug loading capacity, are colloidal nanocarriers with a diameter ranging from 50 nm to 1000 nm and are constructed using scattering melted solid lipid in emulsifier-added water. 64–66 It was first introduced as an effective and promising alternative in 1991 to make up for deficiencies of emulsions, liposomes, and polymeric systems, representing a more excellent vehicle for drug delivery. 67 SLNs usually consist of solid lipids with the drug either loaded on the surface or entrapped inside the cavity.…”